WO2006062807A3 - Compositions with enhanced immunogenicity - Google Patents

Compositions with enhanced immunogenicity Download PDF

Info

Publication number
WO2006062807A3
WO2006062807A3 PCT/US2005/043536 US2005043536W WO2006062807A3 WO 2006062807 A3 WO2006062807 A3 WO 2006062807A3 US 2005043536 W US2005043536 W US 2005043536W WO 2006062807 A3 WO2006062807 A3 WO 2006062807A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
excipients
combination
immunogen
enhanced immunogenicity
Prior art date
Application number
PCT/US2005/043536
Other languages
French (fr)
Other versions
WO2006062807A2 (en
Inventor
Robert L Campbell
Kevin Dolan
Jason Alarcon
John Mikstza
Wendy Woodley
Sheetal Mehta
Original Assignee
Becton Dickinson Co
Robert L Campbell
Kevin Dolan
Jason Alarcon
John Mikstza
Wendy Woodley
Sheetal Mehta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson Co, Robert L Campbell, Kevin Dolan, Jason Alarcon, John Mikstza, Wendy Woodley, Sheetal Mehta filed Critical Becton Dickinson Co
Publication of WO2006062807A2 publication Critical patent/WO2006062807A2/en
Publication of WO2006062807A3 publication Critical patent/WO2006062807A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to immunogenic compositions containing an immunogen and a specific combination of two or more traditional excipients. The excipients in the composition act in combination and enhance immune responses to the immunogen from a subject. The combination of excipients may be used as adjuvant in immunogenic compositions, regardless of route or target of delivery. The compositions can be administered, for example, intradermally, epidermally, transdermally, junctionally, nasally, or subcutaneously.
PCT/US2005/043536 2004-12-06 2005-12-02 Compositions with enhanced immunogenicity WO2006062807A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/006,086 2004-12-06
US11/006,086 US20060121055A1 (en) 2004-12-06 2004-12-06 Compositions with enhanced immunogenicity

Publications (2)

Publication Number Publication Date
WO2006062807A2 WO2006062807A2 (en) 2006-06-15
WO2006062807A3 true WO2006062807A3 (en) 2006-10-12

Family

ID=36574513

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/043536 WO2006062807A2 (en) 2004-12-06 2005-12-02 Compositions with enhanced immunogenicity

Country Status (2)

Country Link
US (1) US20060121055A1 (en)
WO (1) WO2006062807A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8021848B2 (en) * 2001-09-06 2011-09-20 Straus Holdings Inc. Rapid and sensitive detection of cells and viruses
BRPI0417225A (en) * 2003-12-05 2007-03-06 Becton Dickinson Co methods of enhancing the intradermal compartment immune response and compounds useful in said methods
WO2006138572A2 (en) 2005-06-16 2006-12-28 Nektar Therapeutics Al, Corporation Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
EP1896064A2 (en) 2005-06-27 2008-03-12 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2007038478A2 (en) 2005-09-26 2007-04-05 Rapid Micro Biosystems, Inc Cassette containing growth medium
JP2010504970A (en) * 2006-09-26 2010-02-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド Compositions and methods for enhancing adjuvants
CL2007003209A1 (en) * 2006-11-07 2008-05-09 Acambis Inc COMPOSITION THAT INCLUDES A VACCINE OF LIVED FLAVIVIRUS; COMPOSITION THAT INCLUDES A PHARMACEUTICAL PRODUCT DERIVED FROM VIRUS OR PROTEIN; A METHOD FOR THE ELABORATION OF A THERAPEUTIC COMPOSITION THAT INCLUDES TO LIOFILIZE THE COMPOSITION
AU2008339984A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccine
CA2738317C (en) 2008-09-24 2020-01-14 Straus Holdings Inc. Imaging analyzer for testing analytes
EP2496255A4 (en) * 2009-11-05 2014-03-26 Mercia Pharma Inc Adjuvanted nanoparticulate influenza vaccine
CN102037965B (en) * 2011-01-14 2013-11-20 浙江大学 Application of chitosan in prevention and treatment of rice bacterial leaf streak
MX368123B (en) 2011-11-07 2019-09-19 Rapid Micro Biosystems Inc Cassette for sterility testing.
CN103316356B (en) * 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 A kind of recombined lentivirus vector preparation
CN104364388B (en) 2012-04-16 2017-12-19 快速微型生物系统公司 Cell culture apparatus
WO2016130667A1 (en) 2015-02-10 2016-08-18 Ohio State Innovation Foundation Chlamydia-activated b cell platforms and methods thereof
CA3004924A1 (en) * 2015-11-10 2017-05-18 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
WO2018017775A1 (en) * 2016-07-20 2018-01-25 Chesapeake Therapeutics, Llc Methods of attenuating drug excipient cross reactivity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021154A2 (en) * 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
WO2003097669A2 (en) * 2002-05-17 2003-11-27 Københavns Universitet Method for purifying denatured proteins having a desired disulfide bond configuration
US20040013697A1 (en) * 2000-05-30 2004-01-22 Gunther Berndl Self-emulsifying active substance formulation and use of this formulation
US20040087520A1 (en) * 2002-10-25 2004-05-06 Chowdhury Dipak K. Compositions and methods for delivery of therapeutic agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US191056A (en) * 1877-05-22 Improvement in car-heaters
US171253A (en) * 1875-12-21 Improvement in eaves-trough hangers
US170818A (en) * 1875-12-07 Improvement in washing and wringing machines
JPH0688911B2 (en) * 1985-06-06 1994-11-09 国立予防衛生研究所長 Influenza vaccine and method for producing the same
IL99851A (en) * 1990-10-30 1996-06-18 Daiichi Seiyaku Co Muramyldipeptide derivatives and influenza vaccine containing them
US6485729B1 (en) * 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
AT408615B (en) * 1998-09-15 2002-01-25 Immuno Ag NEW INFLUENCE VIRUS VACCINE COMPOSITION
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6494865B1 (en) * 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US7767197B2 (en) * 2000-06-22 2010-08-03 Endo Pharmaceuticals Colorado LLC Delivery vehicle composition and methods for delivering antigens and other drugs
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
BRPI0417225A (en) * 2003-12-05 2007-03-06 Becton Dickinson Co methods of enhancing the intradermal compartment immune response and compounds useful in said methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021154A2 (en) * 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US20040013697A1 (en) * 2000-05-30 2004-01-22 Gunther Berndl Self-emulsifying active substance formulation and use of this formulation
WO2003097669A2 (en) * 2002-05-17 2003-11-27 Københavns Universitet Method for purifying denatured proteins having a desired disulfide bond configuration
US20040087520A1 (en) * 2002-10-25 2004-05-06 Chowdhury Dipak K. Compositions and methods for delivery of therapeutic agents

Also Published As

Publication number Publication date
US20060121055A1 (en) 2006-06-08
WO2006062807A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
WO2006062807A3 (en) Compositions with enhanced immunogenicity
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
TW200643028A (en) Vaccine
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
WO2007130493A3 (en) Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
WO2007068907A3 (en) Vaccine compositions comprising a saponin adjuvant
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
MY143347A (en) Mucosal immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
AU2005332599A8 (en) Polyinosinic acid-polycytidylic acid-based adjuvant
IL154913A0 (en) Composition comprising immunogenic microparticles
WO2006071989A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
WO2006136460A3 (en) New adjuvant
WO2009076158A8 (en) Compositions for inducing immune responses
WO2003059385A3 (en) Hiv vaccine and method of use
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
WO2008008541A8 (en) Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
WO2005074460A3 (en) Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
WO2005058349A3 (en) Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
WO2006114680A3 (en) Vaccine adjuvants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05852696

Country of ref document: EP

Kind code of ref document: A2